Catalym
Oncology Immunotherapy
1 open roleOncology ImmunotherapyMunich, Germany61 employees$261M raisedEst. 2016
Canaan Partners
Bioqube Ventures
Forbion
Omega Funds
Gilde Healthcare
Jeito Capital
About Catalym
- CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
- It focuses on targeting growth differentiation factor 15 (GDF-15) to overcome cancer therapy resistance and improve treatment options.
Catalym is listed on Rocketlist with 1 active role. The company is categorized as Oncology Immunotherapy in BioTech. Catalym is at Series D stage, with a B2B business model, headquartered in Munich, Germany. Catalym was founded in 2016 and has 61 employees. Catalym has raised $261M. Active roles are refreshed daily from public hiring sources.